Form 4: Alnylam Pharmaceuticals Director Colleen F. Reitan Reports Stock Option Grant

Director Colleen F. Reitan reports the acquisition of stock options in Alnylam Pharmaceuticals.

Summary

• On May 16, 2024, Colleen F. Reitan, a director of Alnylam Pharmaceuticals, reported the acquisition of 5,228 stock options.
• The options have an exercise price of $151.22.
• The options vest in full on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
• The expiration date for the options is May 16, 2034.
• Reitan also granted a Limited Power of Attorney for Section 16 reporting obligations, effective May 16, 2024, to Jeffrey Poulton, Brett Budzinski, Gisele Dion, and Stephen Hall.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their directors and officers.
• The vesting schedules and exercise prices are typically structured to align with the company's long-term performance goals.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates